Abstract
Using electronic health record data combined with primary chart review, we identified 7 children across 8 pediatric medical centers with a diagnosis of Multisystem Inflammatory Syndrome in Children (MIS-C) who were managed as outpatients. These findings should prompt a discussion about modifying the case definition to allow for such a possibility.
Competing Interest Statement
Dr. Jhaveri is a consultant for AstraZeneca, Seqirus and Dynavax, and receives an editorial stipend from Elsevier. Dr. Mejias reports funding from Janssen, Merck for research support, and Janssen, Merck and Sanofi-Pasteur for Advisory Board participation; Dr. Schulert reports consulting fees from Novartis and SOBI; Dr. Rao reports prior grant support from GSK and Biofire and is a consultant for Seqirus.
Funding Statement
This research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program of research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Children's Hospital of Philadelphia's institutional review board designated this study as not human subjects research and waived the need for consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding Source: This research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program of research.
Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the RECOVER Program, the NIH or other funders.
Conflicts of Interest: Dr. Jhaveri is a consultant for AstraZeneca, Seqirus and Dynavax, and receives an editorial stipend from Elsevier. Dr. Mejias reports funding from Janssen, Merck for research support, and Janssen, Merck and Sanofi-Pasteur for Advisory Board participation; Dr. Schulert reports consulting fees from Novartis and SOBI; Dr. Rao reports prior grant support from GSK and Biofire and is a consultant for Seqirus.
Authorship has been determined according to ICMJE recommendations.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
